Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk
Metrics: PDF 710 views | HTML 862 views | ?
Jie Gao1,*, Nan Gai2,*, Li Wang1,*, Kang Liu3, Xing-Han Liu3, Lin-Ting Wei1, Tian Tian3, Shan-Li Li3, Yi Zheng3, Yu-Jiao Deng3, Zhi-Jun Dai3 and Rong-Guo Fu1
1 Department of Nephrology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 Department of Rheumatic Immunology, Xi’an No.5 Hospital, Xi’an, China
3 Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
* These authors have contributed equally to this work
Jie Gao, email:
Rong-Guo Fu, email:
Keywords: PDCD1; SLE; polymorphism; risk; meta-analysis
Received: December 27, 2016 Accepted: February 28, 2017 Published: March 18, 2017
The association of polymorphisms in programmed cell death 1 (PDCD1) gene with systemic lupus erythematosus (SLE) risk is inconsistent across different studies. This meta-analysis is aimed to provide reliable evidence to the association of five common PDCD1 polymorphisms (PD1.1, PD1.2, PD1.3, PD1.5 and PD1.6) with SLE risk. A total of 28 studies with 4,344 SLE cases and 5,474 healthy controls were included in this meta-analysis. PD1.3 polymorphism was significantly associated with SLE in the overall population (A vs. G: OR = 1.35, 95% CI = 1.12-1.63; GA vs.GG: OR = 1.41, 95% CI = 1.12-1.76; AA+GA vs. GG: OR = 1.41, 95% CI = 1.13-1.7). In the stratified analyses based on ethnicity, we found a significant association in Caucasians and in Mexicans. In the subgroup analyses by gender, a significant association was found between PD1.3 polymorphism and SLE risk in males. The results also suggested an association between the PD1.6 polymorphism and decreased SLE risk (A vs. G: OR = 0.84, 95% CI = 0.73-0.96). Our meta-analysis revealed that PD1.3 polymorphism may increase the susceptibility to SLE, particularly in Caucasians, while PD1.6 may be a protective factor to SLE.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.